Boston Scientific lowers profit forecast on China and heart-device woes

Boston Scientific is bracing for a difficult 2027, warning that a combination of pricing pressure in China and slowing demand for key heart-device technologies will likely stifle revenue and earnings growth. The medtech giant lowered its full-year profit forecast on Wednesday, triggering a 5.3% drop in share price as investors reacted to the outlook for its core growth drivers.

The company now expects 2026 adjusted profit to fall between $3.16 and $3.18 per share, a notable dip from its previous projection of $3.28 to $3.32. This shift puts the company below the average analyst expectation of $3.23 per share, according to data from LSEG. The immediate future looks equally lean; fourth-quarter sales are expected to slide between 1% and 3% year over year, with adjusted earnings projected at 77 to 79 cents per share—missing the 83 cents analysts had anticipated, Reuters reported.

China’s bulk buying squeezes margins

The primary headwind is a collapse in pricing power within the Chinese market. Beijing’s volume-based procurement (VBP) program—a system where the government purchases medical devices in bulk at sharply lower prices—is altering the economics of the region.

Vertiv Rises, GE Healthcare Jumps, Boston Scientific Slumps as Profit Outlook Falls Short |…

Chief Executive Mike Mahoney noted that these pricing headwinds will persist well into 2027. The impact is particularly acute in the company’s endoscopy business, where the pressure to lower prices is creating a ceiling on growth.

Watchman implant slump pressures cardiac portfolio growth

Beyond the pricing wars, the company is facing struggles with its cardiac portfolio. Specifically, the Watchman implant—a device designed to prevent blood clots and strokes—has seen a “softer uptake” in recent quarters.

Boston Scientific Stock (BSX) Earnings Today: Medical Device Growth & Outlook

The stakes here involve the company’s ability to offset losses. Mahoney warned that growth in other areas likely won’t be enough to counteract the combined pressure from the Watchman slump and challenges in electrophysiology.

The financial friction is further compounded by the cost of expansion. Boston Scientific’s $14.5 billion acquisition of Penumbra has been pushed back to the first quarter of 2027 due to longer regulatory reviews. This delay is more than just a calendar issue; in a high-interest-rate environment, the cost of financing such a massive deal increases, turning a strategic acquisition into a heavier drag on earnings.

Boston Scientific Corp ($BSX) Q3 2026 Earnings Call

The broader medtech trade-off

CFO Jon Monson was blunt about the trajectory, stating, We anticipate continued top-line pressure into 2027, which we expect will make it challenging to grow revenue and adjusted earnings per share.

The company now finds itself caught between a regulatory squeeze in Asia, a cooling market for its stroke-prevention tech, and the rising cost of borrowing to buy its way into new growth.